Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-548

First Posted Date: 2022-07-13

Last Posted Date: 2024-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT05455502

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Phase 3

Active, not recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-07-05

Last Posted Date: 2024-08-13

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 822

Registration Number: NCT05444257

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 192 locations

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-06-29

Last Posted Date: 2023-03-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 16

Registration Number: NCT05437120

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
GCP Research, Saint Petersburg, Florida, United States

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Phase 3

Recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-06-16

Last Posted Date: 2025-06-19

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 210

Registration Number: NCT05422222

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Stanford University Clinical and Translational Research Unit, Palo Alto, California, United States
🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States

and more 34 locations

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: VX-150

First Posted Date: 2022-06-14

Last Posted Date: 2022-10-14

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 45

Registration Number: NCT05418712

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Phase 3

Recruiting

Conditions: Thalassemia
Genetic Diseases, Inborn
Beta-Thalassemia
Hematologic Diseases
Hemoglobinopathies

Interventions: Biological: CTX001

First Posted Date: 2022-05-02

Last Posted Date: 2025-02-24

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 15

Registration Number: NCT05356195

Locations: 🇺🇸
SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States
🇨🇦
The Hospital for Sick Children, Toronto, Canada
🇩🇪
Universitätsklinikum Düsseldorf Hospital Duesseldorf, Düsseldorf, Germany

and more 3 locations

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Phase 1

Completed

Conditions: Acute Pain

Interventions: Drug: Placebo
Drug: VX-708

First Posted Date: 2022-04-26

Last Posted Date: 2023-05-15

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 100

Registration Number: NCT05347394

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Phase 3

Recruiting

Conditions: Hydroxyurea Intolerance
Sickle Cell Disease
Hydroxyurea Failure
Hemoglobinopathies
Hematological Diseases

Interventions: Biological: CTX001

First Posted Date: 2022-04-15

Last Posted Date: 2024-10-17

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 15

Registration Number: NCT05329649

Locations: 🇺🇸
Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 4 locations

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Phase 3

Active, not recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2022-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 297

Registration Number: NCT05331183

Locations: 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇧🇪
Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Brussel - Campus Jette, Brussels, Belgium

and more 78 locations

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Phase 1

Completed

Conditions: APOL1-mediated Kidney Disease

Interventions: Drug: VX-840
Drug: Placebo

First Posted Date: 2022-04-12

Last Posted Date: 2022-12-08

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 88

Registration Number: NCT05324410

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy